 This issue of JCP Visuals is available in Adobe Acrobat Portable Document Format (PDF). For a description of PDF and Adobe Acrobat Reader, please visit our Online Media Page. Download the Posttest (if you prefer not to take the Posttest online for instant credit) |
To obtain credit, please
study the activity material and complete the posttest as
instructed. CME Objectives After completing this educational activity, participants should be able to:
Statement of Need and Purpose Although treatment-resistant depression and anxiety are serious public health issues, there is little research in the area to guide clinicians. Atypical antipsychotics have been reported useful for treatment-resistant depression and anxiety in a few small studies, but additional clinical trials are necessary. This activity was designed to meet the needs of participants in CME activities provided by Physicians Postgraduate Press, Inc. who have requested information on managing patients with treatment-resistant depression and anxiety. There are no prerequisites for participating in this activity. Accreditation Statement Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Physicians Postgraduate Press, Inc. designates this educational activity for up to 1 Category 1 credit toward the AMA Physician's Recognition Award. Each participant should claim only those credits that he/she actually spent in the educational activity. Date of Original Release/Review This JCP Visuals was published in April 2004 and is eligible for CME credit through April 30, 2006. The latest review of this material was February 2004. Faculty Charles B. Nemeroff, M.D., Ph.D., Chair Pierre Blier, M.D., Ph.D. Dennis S. Charney, M.D. Martin B. Keller, M.D. Mark H. Pollack, M.D. Faculty Disclosure In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this continuing medical education activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Nemeroff has received grant/research support from Abbott, American Foundation for Suicide Prevention, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Merck, National Alliance for Research on Schizophrenia and Depression, National Institute of Mental Health, Pfizer, Stanley Foundation/NAMI, and Wyeth; is a consultant for Abbott, Acadia Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Corcept, Cypress Bioscience, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Neurocrine Biosciences, Novartis, NPS Pharmaceuticals, Organon, Otsuka, Sanofi-Synthelabo, Scirex, Somerset, and Wyeth; is a member of the speakers bureaus for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Organon, Otsuka, Pfizer, and Wyeth; is a stockholder for Corcept and Neurocrine Biosciences; is on the boards of directors for American Foundation for Suicide Prevention, Cypress Bioscience, George West Mental Health Foundation, Novadel Pharma, and Heinz C. Prechter Fund for Manic Depression; and holds patents on method and devices for transdermal delivery of lithium (US 6,375,990 B1), and method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing, April 2001). Dr. Blier has received grant/research support Janssen, Eli Lilly, and Forest; is on the speakers/advisory boards for Janssen, Eli Lilly, Forest, and Lundbeck; and has presented expert testimony for Eli Lilly. Dr. Keller is a consultant for and has received honoraria from Bristol-Myers Squibb, Collegium, Cypress Bioscience, Cyberonics, Eli Lilly, Forest, Janssen, Merck, Organon, Otsuka, Pfizer, Pharmacia, Pharmastar, Seprecor, Vela, and Wyeth; has received grant/research support from Eli Lilly, Forest, Merck, Organon, Pfizer, and Wyeth; and is a member of the advisory boards for Abbott, Bristol-Myers Squibb, Cephalon, Cyberonics, Cypress Bioscience, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Merck, Mitsubishi Pharma, Novartis, Organon, Pfizer, Pharmacia, Sanofi-Synthelabo, Scirex, Sepracor, Somerset, Vela, and Wyeth. Dr. Pollack is on the advisory boards for Bristol-Myers Squibb, Cephalon, Forest, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Otsuka, Pfizer, Roche, UCB Pharma, and Wyeth; has received grant/research support from Cephalon, Forest, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, UCB Pharma, and Wyeth; and is involved with speaker programs for Forest, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, Solvay, and Wyeth. Dr. Charney has no affiliations or other relationships to disclose relevant to the presentation. Disclosure of Off-Label Usage The chair has determined that, to the best of his knowledge, ketamine, memantine, olanzapine, riluzole, and risperidone are not approved by the U.S. Food and Drug Administration for the treatment of depression. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Acknowledgment This JCP Visuals was derived from the planning roundtable “New Therapies for Treatment-Resistant Depression and Anxiety” held September 28–29, 2003, in Atlanta, Ga. The roundtable and this JCP Visuals were independently developed by the CME Institute of Physicians Postgraduate Press, Inc. pursuant to an unrestricted educational grant from Janssen Pharmaceutica Products, L.P. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter. |